Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium + bacillus licheniformis
- Development stage
- Unknown
- Lead developer
- Beijing Friendship Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
bifidobacterium + bacillus licheniformis is a probiotic combination therapy being investigated for its potential to modulate the gut-brain axis in patients with Parkinson's disease. This microbial therapy consists of live *Bifidobacterium* species (such as *B. infantis* or *B. longum*) and *Bacillus licheniformis*. *Bifidobacterium* is a genus of anaerobic bacteria that helps maintain intestinal homeostasis and produces short-chain fatty acids (SCFAs), which have anti-inflammatory properties. *Bacillus licheniformis* is a spore-forming bacterium that consumes oxygen in the intestinal tract, creating an environment conducive to the growth of beneficial anaerobic flora. In the context of Parkinson's disease, this combination is primarily used to alleviate gastrointestinal symptoms like constipation and is being studied for its ability to reduce neuroinflammation and potentially slow disease progression by restoring gut microbiota balance. Clinical research led by Beijing Friendship Hospital and Capital Medical University has explored the efficacy of these probiotics in improving both motor and non-motor symptoms of the disease.
- Brand names
- BifidotriplePeifeikang
- Other names
- Bifidobacterium and Bacillus licheniformis capsulesBifidobacterium infantis + Bacillus licheniformis
Beyond the preview
Go deeper on bifidobacterium + bacillus licheniformis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium + bacillus licheniformis.